Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
Argus Health
Baxter
Daiichi Sankyo
Johnson and Johnson
Julphar
Dow
Medtronic

Generated: May 28, 2018

DrugPatentWatch Database Preview

NAMENDA Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Namenda patents expire, and what generic alternatives are available?

Namenda is a drug marketed by Allergan Sales Llc and Forest Labs Llc and is included in three NDAs. There are seven patents protecting this drug and five Paragraph IV challenges.

The generic ingredient in NAMENDA is memantine hydrochloride. There are twenty-eight drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the memantine hydrochloride profile page.
Drug patent expirations by year for NAMENDA
Pharmacology for NAMENDA
Medical Subject Heading (MeSH) Categories for NAMENDA
Synonyms for NAMENDA
(3,5-Dimethyl-1-adamantyl)amine hydrochloride
1-amino-3,5-dimethyl-adamantane hydrochloride
1-Amino-3,5-dimethyladamantane Hydrochloride
1,3-Dimethylaminoadamantane hydrochloride
19982-08-2 (Parent)
3,5-Dimethyl-1-adamantanamine hydrochloride
3,5-Dimethyl-1-adamantanamineHydrochloride
3,5-Dimethyl-1-aminoadamantane HCl
3,5-Dimethyl-1-aminoadamantane hydrochloride
3,5-Dimethyl-tricyclo[3.3.1.13,7]decan-1-amine hydrochloride
3,5-dimethyladamantan-1-amine hy-drochloride
3,5-dimethyladamantan-1-amine hydrochloride
3,5-dimethyladamantan-1-amine;hydrochloride
3,5-dimethyladamantan-1-aminium chloride
3,5-dimethyladamantanylamine, chloride
3,5-Dimethylamantadine hydrochloride
3,5-dimethyltricyclo(3.3.1.1(3,7))decan-1-amine hydrochloride
3,5-Dimethyltricyclo(3.3.1.1(sup 3,7))decan-1-amine hydrochloride
3,5-Dimethyltricyclo(3.3.1.13,7)decan-1-amine hydrochloride
3,5-dimethyltricyclo[3.3.1.13,7]decan-1-amine hydrochloride
41100-52-1
4CH-006120
AB0013351
AB2000447
AC-559
AC1L492E
ACMC-209jif
AK-44671
Akatinol
AKOS015889460
AM20070534
AN-15700
ANW-29557
AOB5318
AS-13331
AX8033628
Axura
BC208848
BCP9000253
BG0374
BR-44671
CCG-39018
CHEBI:64323
CHEMBL1699
CPD000058926
CPD000875213
CS-2422
CTK8B1656
D 145
D-145
D04905
D3608
Ebixa
Ebixza
EINECS 255-219-6
EU-0100861
FT-0650723
H908
HMS1571C17
HMS1921H03
HY-B0365A
I01-2072
J10287
JY0WD0UA60
KS-00000X1M
KSC911M5N
LDDHMLJTFXJGPI-UHFFFAOYSA-N
LP00861
M 9292
M-2015
Mantine
MCULE-6635165082
Memantin hydrochloride
Memantine (hydrochloride)
Memantine HCL
MEMANTINE HYDROCHLORIDE
Memantine hydrochloride (JAN/USAN)
Memantine hydrochloride (Namenda)
Memantine hydrochloride [USAN]
memantine.HCl
Memantinehydrochloride
Memary
Memary (TN)
MFCD00214336
MLS001332605
MLS001332606
MolPort-003-666-358
MRZ-2/145
N06DX01
Namenda (TN)
Namenda XR
NC00680
NCGC00094186-01
NCGC00094186-02
NCGC00094186-03
NCGC00261546-01
NMI-131
NSC 102290
NSC-102290
NSC-757843
NSC102290
NSC757843
Pharmakon1600-01501121
RTR-016345
s2043
SAM001246743
SAM002699890
SBB003390
SCHEMBL3053
SMR000875213
SPECTRUM1501121
SR-01000075458
SR-01000075458-1
ST088119
SUN Y7017
SUN-Y7017
Tox21_500861
TR-016345
Tricyclo(3.3.1.1(3,7))decan-1-amine, 3,5-dimethyl-, hydrochloride
Tricyclo(3.3.1.1(sup 3,7))decan-1-amine, 3,5-dimethyl-, hydrochloride
UNII-JY0WD0UA60
Z1551429722

US Patents and Regulatory Information for NAMENDA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-004 Jun 21, 2010 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-004 Jun 21, 2010 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-004 Jun 21, 2010 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Sales Llc NAMENDA memantine hydrochloride SOLUTION;ORAL 021627-001 Apr 18, 2005 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for NAMENDA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc NAMENDA memantine hydrochloride TABLET;ORAL 021487-001 Oct 16, 2003 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc NAMENDA memantine hydrochloride SOLUTION;ORAL 021627-001 Apr 18, 2005 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc NAMENDA memantine hydrochloride TABLET;ORAL 021487-002 Oct 16, 2003 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc NAMENDA memantine hydrochloride TABLET;ORAL 021487-001 Oct 16, 2003 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for NAMENDA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2007-10-16
➤ Subscribe Extended-release Capsules 28 mg ➤ Subscribe 2013-06-12
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg, and 28 mg ➤ Subscribe 2013-06-10
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg, and 28 mg ➤ Subscribe 2013-08-16
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg ➤ Subscribe 2013-06-17

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Teva
Colorcon
Chinese Patent Office
Boehringer Ingelheim
Julphar
Chubb
Accenture
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.